Scalone G, Brugaletta S, Gomez O, Otsuki S, Sabate M
Thorax Institute. Department of Cardiology IDIBAPS: Institut d'Investigacions Biomediques Agust Pi i Sunyer (IDIBAPS) Hospital Clinic, Barcelona, Spain -
Panminerva Med. 2015 Mar;57(1):1-13. Epub 2014 Nov 6.
Bioresorbable vascular scaffolds (BVS) are considered the fourth revolution in Interventional Cardiology, thus promising to address some of the pending issues with current-generation drug eluting stents (DES). Notably, most of the potential advantages of BVS over other current devices are due to a peculiar vascular response, called "vascular restoration therapy". The emerging data from real-world expanded use registries suggest that BVS use is feasible in a wide variety of patients (from low- to high- risk), and lesions (from simplex to complex). However, few safety concerns with currently available BVS have arised from initial experiences all over the word. Data from ongoing large-scale randomized controlled trials will be able to demonstrate whether BVS improve patient early and long-term outcomes compared to best-in-class DES.
生物可吸收血管支架（BVS）被视为介入心脏病学的第四次革命，有望解决当前一代药物洗脱支架（DES）的一些悬而未决的问题。值得注意的是，与其他现有器械相比，BVS的大多数潜在优势归因于一种特殊的血管反应，即“血管修复疗法”。来自现实世界扩大使用登记处的新数据表明，BVS在各种各样的患者（从低风险到高风险）和病变（从简单到复杂）中使用是可行的。然而，世界各地的初步经验引发了对目前可用BVS的一些安全担忧。正在进行的大规模随机对照试验的数据将能够证明与同类最佳DES相比，BVS是否能改善患者的早期和长期预后。
